A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Inclusion Criteria

• •Solid tumor, advanced or metastatic, progressed on standard treatment participants in Arm B must have either triple negative breast cancer OR urothelial carcinoma OR ovarian cancer OR have a solid tumor with a deleterious mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D
• •Measurable disease per RECIST v1.1
• •Adequate organ function
• •Eastern Cooperative Oncology Group (ECOG) 0 or 1
• •Tumor tissue for genomic analysis
• •Histologically or cytologically confirmed solid tumor, previously treated and measurable per RECIST v1.1, as follows:
• •Arm A: ovarian cancer with gBRCAwt disease, either platinum-sensitive OR platinum-resistant
• •Arm B: Metastatic triple negative breast cancer OR advanced/ metastatic urothelial carcinoma OR relapsed ovarian cancer
• •At least 1 prior line of standard therapy for advanced disease
• •Adequate organ function
• •ECOG 0 or 1
• •Tumor tissue for genomic analysis